Pharmaceutical Executive

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer, and much more.

UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss: Counterfeit weight loss drugs (particularly fake Ozempic) and potential health risks What can be done to raise awareness among consumers about the dangers of counterfeit medications Ways increase access to legitimate weight loss medications, especially for those in underserved communities and much more!

Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses how is they're positioning to capitalize on the unmet needs in other specific therapeutic areas, their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.

In this episode of the Pharmaceutical Executive podcast, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon discusses: The broader societal implications of these maternal health issues highlighted in The Commonwealth Fund study The most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make Specific efforts Organon is undertaking to invest in research, education, and its pipeline to focus on critical areas of need in maternal health How her in-practice experience as an OB-GYN are informing Organon's strategic approach to addressing maternal health challenges and more!

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts and the main factors that are contributing to the closures of both large and independent pharmacies, what alternative solutions can help ensure continued access to medications for all Americans (particularly those in underserved communities), some potential long term consequences if these pharmacy closures continue, and so much more

Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses: Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs What needs to be done for GLP-1s to be covered Steps companies developing weight-loss medications should take to ensure responsible and ethical practice Advice for investors and financiers who are considering entering the weight-loss medication market

Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more. Link to Honeycomb Health video: https://www.pharmexec.com/view/going-beyond-visuals-to-connect-with-diverse-audiences

Currax Pharmaceuticals CEO, George Hampton discusses what patient success has looked like for their oral anti-obesity medication, how expanded access can help with the world's obesity epidemic, when prices should come down, and much more. 

In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.  Featured in this episode are: Emma Banks, CEO, ramarketing Jill Jaroch, Senior Director, Women’s Health & Urology Marketing, Astellas Marie Teil, Global Head, UCB’s Women of Childbearing Age Program Julia Lakeland, Chief Product Office, uMotif If you enjoyed this episode of our podcast, we encourage you to seek out the longer version of each of these videos—Linked on our website! 

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses their recent data and research about some massive behavioral shifts occurring across Gen-Z, and how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract the ever elusive generation. 

Jingsong Wang, Chairman of Nona Biosciences, discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033, an innovative antibody-drug conjugate (ADC) targeting MSLN, a key antigen in various solid tumors. Wang believes that the partnership will significantly advance Nona's Harbour Mice® platform and ADC ecosystem.

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more. 

Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene, discusses findings from their new study about Reshaping Pharmacovigilance in the age of AI, digital/generative AI opportunities, how quickly the industry is adopting this technology, and much more.

Dr. Julien Boisdron, Global Head of OneMedical / Chief Medical Officer Roche Diabetes Care, discusses the current standard for diabetes care, the importance of patient advocacy and mental health, what the future of this space holds, and much more. 

Edward Triebell, Commercial Executive Director for MRN Technologies, discusses the biggest digital trends in clinical research right now, how COVID-19 impacted the use of digital within sponsors and CROs, what the future of DCT services looks like, and much more.

David Klein, co founder and CEO of Click Therapeutics, discusses the new FDA SaMD guidance, the clear differences between companion apps and SaMD, and gives insight into what to expect from this combination in the future.

In this exclusive Pharm Exec Podcast episode with Paul Biondi, executive partner at Flagship Pioneering (the venture creation firm behind Moderna and many other life science firms) and president of Pioneering Medicines, Meg Rivers, managing editor, asks Biondi about 1) the process of founding a company; 2) what factors they consider when deciding whether to partner with a pharmaceutical company (like your partnership with Novo Nordisk) or a foundation (like your partnership with the Cystic Fibrosis Foundation)—along with what makes one organization stand out from another; 3) where science is booming in pharma right now; 4) deciding whether to found a company looking to launch innovations in an existing space vs. pursue innovations in an untapped space; and 5) signs that a company will achieve commercial success from early on.

Commercialization is a tough road to navigate even for the most established bio/pharmaceutical therapies. But as cell and gene therapies (CGTs) continue to form roots and make a splash worldwide—but specifically in the US—commercialization forms its own version of standardization and best practices. In this exclusive interview with Pharmaceutical Executive, Lung-I Cheng, vice president of CGT, Cencora (formerly AmerisourceBergen), discusses: 1) defining CGT commercialization strategies and foundational knowledge—and the best music metaphor 2) what he wishes companies knew about commercialization strategies 3) common knowledge gaps of CGTs 4) how CGT developers can overcome key challenges, including those related to patient access, regulatory requirements, and market access 5) how planning for allogeneic cell therapies differs from autologous cell therapies and gene therapies 6) how companies can demonstrate CGT value as more products enter the development pipeline (and competition intensifies) 7) when to start planning a CGT commercialization strategy 8) predictions for the CGT market in five years

Gerald Kierce, co founder and CEO of Trustible and Andrew Gamino-Cheong, the company's CTO and co founder, delve into the realm of artificial intelligence discussing Trustible's mission and its pioneering efforts to ensure ethical AI use particularly in the pharmaceutical industry, and how it navigates complex AI regulations across the globe.

How to price a bio/pharmaceutical drug is one of the most complex topics for pharmaceutical executives, as there are many factors to consider. Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, reveals the following to Pharmaceutical Executive® in this exclusive Pharm Exec Podcast interview: 1) the biggest drug pricing challenges today; 2) current efforts to lower drug pricing; 3) what companies should consider as it relates to drug pricing from a legal perspective; 3) the status of the Inflation Reduction Act (IRA), specifically what should companies be watching for; 4) potential impact on companies from the IRA; 5) IRA milestones we will be seeing through the end of the year; and 6) drug pricing recommendations (from a legal perspective). ACT podcast: https://www.appliedclinicaltrialsonline.com/editorial-podcasts